Spots Global Cancer Trial Database for domvanalimab
Every month we try and update this database with for domvanalimab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study Comparing the Combination Domvanalimab and Zimberelimab With Pembrolizumab in Untreated Locally Advanced or Metastatic PD-L1-High Non-Small Cell Lung Cancer | NCT04736173 | Non Small Cell ... Nonsquamous Non... Squamous Non Sm... Lung Cancer | Domvanalimab Zimberelimab Carboplatin Paclitaxel Pemetrexed Pembrolizumab | 18 Years - | Arcus Biosciences, Inc. | |
| Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma | NCT05130177 | Melanoma | Zimberelimab Domvanalimab | 18 Years - | University of Pittsburgh | |
| Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer | NCT04262856 | Non Small Cell ... Nonsquamous Non... Squamous Non Sm... Lung Cancer | Domvanalimab Etrumadenant Zimberelimab | 18 Years - | Arcus Biosciences, Inc. | |
| Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer | NCT04791839 | Non Small Cell ... Non-small Cell ... Non-small Cell ... | Zimberelimab Domvanalimab Etrumadenant | 18 Years - | Washington University School of Medicine | |
| Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer | NCT04791839 | Non Small Cell ... Non-small Cell ... Non-small Cell ... | Zimberelimab Domvanalimab Etrumadenant | 18 Years - | Washington University School of Medicine | |
| A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies | NCT03628677 | Solid Tumor, Un... | Domvanalimab Zimberelimab | 18 Years - | Arcus Biosciences, Inc. | |
| A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body | NCT05568095 | Advanced Upper ... | Domvanalimab Zimberelimab Capecitabine Fluorouracil Leucovorin Oxaliplatin Nivolumab | 18 Years - | Arcus Biosciences, Inc. | |
| PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder Cancer | NCT06133517 | Urothelial Blad... | Sacituzumab gov... Zimberelimab Domvanalimab | 18 Years - | Fundación para el Progreso de la Oncología en Cantabria | |
| A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body | NCT05568095 | Advanced Upper ... | Domvanalimab Zimberelimab Capecitabine Fluorouracil Leucovorin Oxaliplatin Nivolumab | 18 Years - | Arcus Biosciences, Inc. | |
| Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread | NCT03547973 | Metastatic Urot... | Sacituzumab Gov... Pembrolizumab Cisplatin Avelumab Zimberelimab Carboplatin Gemcitabine Domvanalimab | 18 Years - | Gilead Sciences | |
| A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies | NCT05329766 | Gastrointestina... | Domvanalimab Quemliclustat Zimberelimab Fluorouracil Leucovorin Oxaliplatin | 18 Years - | Arcus Biosciences, Inc. | |
| Study With Immunotherapy Combinations in Participants With Metastatic Non-Small Cell Lung Cancer | NCT05676931 | Advanced Non-Sm... | Domvanalimab Quemliclustat Zimberelimab Docetaxel Platinum-Based ... | 18 Years - | Arcus Biosciences, Inc. | |
| Switch Maintenance in Pancreatic | NCT05419479 | Pancreatic Canc... Adenocarcinoma ... Squamous Cell C... Adenosquamous C... | ZIMBERELIMAB DOMVANALIMAB APX005M FOLFIRI | 18 Years - | Dana-Farber Cancer Institute | |
| Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer | NCT05502237 | Non-small Cell ... | Zimberelimab Domvanalimab Pembrolizumab Carboplatin Cisplatin Paclitaxel Nab-paclitaxel Pemetrexed | 18 Years - | Gilead Sciences |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
